Exhibit 10.13

       Credit Facility Letter dated as of January 1, 2005 between Ardent
                 Pharmaceuticals, Inc. and Bioaccelerate, Inc.

                                Bioaccelerate Inc

                                1st January, 2005

Ardent Pharmaceuticals, Inc.
631 United Drive, Suite 200

Durham, NC 27713
Attn:  President and CEO

      Re:   Credit Facility

Gentlemen:

BIOACCELERATE INC  ("BIOACCELERATE  INC") is pleased to make available to Ardent
Pharmaceuticals,  Inc. (the  "Company") a senior,  secured credit  facility (the
"Credit  Facility"),  pursuant  to which  BIOACCELERATE  INC shall  provide  the
Company one or more loans (each, a "Tranche") in the aggregate  principal amount
of up to Two Million Dollars ($2,000,000) dollars (the "Maximum Funded Amount"),
subject to the terms and  conditions  as  hereinafter  provided  in this  letter
agreement (this "Letter Agreement").

The First Tranche (the "Initial  Tranche") will be payable to the Company or its
Creditors  on an as  needed  basis  in  conjunction  with  a  budget  agreed  by
BiIOACCELERATE  INC and will be provided  and funded to the Company upon receipt
of the following  documents from the Company:  (i) a grid  promissory  note (the
"Note"),  executed  by an  authorized  officer  of the  Company  evidencing  the
principal  amount of funds available under the Credit Facility and the draw down
of the  Initial  Tranche  (in the form  attached  hereto as Exhibit  A),  (ii) a
security  agreement (the "Security  Agreement") and other  collateral  documents
pursuant to which certain assets and subsequently acquired assets of the Company
shall be pledged to secure the  repayment of the  indebtedness  evidenced by the
Note (the  "Security  Documents"),  executed  by an  authorized  officer  of the
Company  (in the form  attached  hereto as Exhibit  B),  (iii) the  warrant  (as
defined  herein),  executed by an authorized  officer of the Company,  (iv) such
other documents,  each in form and substance  satisfactory to BIOACCELERATE INC,
as  BIOACCELERATE  INC  shall  reasonably  request.  Subject  to the  conditions
specified herein, additional Tranches shall be made available on as needed basis
(each a "Funding Date").  Each Additional  Tranche will be funded within two (2)
business  days  following  receipt by  BIOACCELERATE  INC on a Funding Date of a
request for the funding of an Additional  Tranche (each,  a "Request")  from the
Company.

The  Company  covenants  to use the  proceeds  of each  Tranche  solely  for the
purposes as agreed with  BIOACCELERATE  INC. In  connection  with the  foregoing
covenant, BIOACCELERATE INC shall have the right (the "Audit and Demand Right"),
subject to customary confidentiality  provisions, at any time during the term of
the  Note  and  for  such  extended  period  of  time  as  indebtedness  remains
outstanding under any Note to (a) audit and inspect the books and records of the
Company for the purpose of  determining  the use of proceeds from any Tranche at
reasonable  times and with reasonable  prior notice in accordance with the terms
and  conditions of the Note or (b) demand  reasonable  evidence from the Company
that the Company is in compliance  with the foregoing  covenant,  which evidence
the Company shall provide to BIOACCELERATE INC promptly upon written request.


                                      -1-
<PAGE>

Notwithstanding   anything  to  the  contrary   provided  herein  or  elsewhere,
BIOACCELERATE  INC shall have no  obligation  to fund a Tranche if at the time a
Request is received by  BIOACCELERATE  INC and prior to when the funds requested
in the  Tranche  are  sent,  one or  more of the  following  events  shall  have
occurred:

      (iv)  There  shall be any  material  change in the  business,  properties,
assets,  results of operations,  prospects or financial condition of the Company
since December 31, 2004,  except as represented  and disclosed to  BIOACCELERATE
INC;

      (v) The  Company  shall be in breach  of or  default  under  any  material
contract, license or other agreement or instrument; or

      (vi) There  shall not have  occurred  (a) any  domestic  or  international
event,  act or occurrence  which has materially  disrupted,  or is likely in the
immediate future to materially disrupt,  the securities  markets;  (b) a general
suspension of, or a general  limitation on prices for,  trading in securities on
the  New  York  Stock  Exchange  or  the  American  Stock  Exchange  or  in  the
over-the-counter market; (c) any outbreak of major hostilities or other national
or international  calamity;  (d) any banking  moratorium  declared by a state or
federal  authority;  (e) any moratorium  declared in foreign exchange trading by
major international banks or other persons; (f) any material interruption in the
mail service or other means of communication  within the United States;  (g) any
change in the market for  securities in general or in political,  financial,  or
economic  conditions;  or (h)  neither  the  Company  nor  any of its  officers,
directors and/or controlling  shareholders have become the subject of or a named
party in any investigation or action involving any regulatory or self-regulatory
organization  including,  but not  limited  to,  the SEC,  the NASD or any state
and/or  federal  agency  (each as set forth in this  clause  (iii),  a "Pro Rata
Event").

As an  inducement  to  BIOACCELERATE  INC to provide the Credit  Facility to the
Company, the Company's Parent, Enhance Biotech Inc, shall issue to BIOACCELERATE
INC (on the date of the funding of the Initial  Tranche)  five (5) year warrants
(the  "Warrants") to purchase  750,000 shares of the Company's common stock (the
"Common Stock"),  at an exercise price of $3.00 per share (subject to adjustment
for anti-dilution and other customary adjustments) .

This  Agreement  shall be  governed  by and  construed  in  accordance  with the
internal  laws of the State of New York without  regard to the conflicts of laws
principles thereof.  The parties hereto hereby agree that any suit or proceeding
arising directly and/or  indirectly  pursuant to or under this instrument or the
consummation of the transactions contemplated hereby, shall be brought solely in
a federal or state court  located in the City,  County and State of New York. By
its execution hereof,  the parties hereby covenant and irrevocably submit to the
in personam  jurisdiction  of the federal and state courts  located in the City,
County and State of New York and agree that any  process in any such  action may
be served upon any of them  personally,  or by certified mail or registered mail
upon them or their agent, return receipt requested, with the same fall force and
effect as if personally  served upon them in New York City.  The parties  hereto
waive any claim that any such  jurisdiction  is not a  convenient  forum for any
such suit or proceeding and any defense or lack of in personam jurisdiction with
respect  thereto.  In the  event of any such  action  or  proceeding,  the party
prevailing  therein  shall be entitled to payment from the other party hereto of
its  reasonable   counsel  fees  and   disbursements  in  an  amount  judicially
determined.


                                      -2-
<PAGE>

Any notice,  consent,  request,  or other communication given hereunder shall be
deemed sufficient if in writing and sent by registered or certified mail, return
receipt  requested  addressed to the Company,  at its principal  office as first
provided  above,  Attention:  Phillip  Wise.  And  to  BIOACCELERATE  INC at its
addressed  provided above (or to such other address as either the Company and/or
BIOACCELERATE INC shall provide in writing to the other party). Notices shall be
deemed to have been given on the date of receipt by the other party.

                                    Very truly yours,

                                    BIOACCELERATE, INC.

                                    By: /s/ Linden Boyne
                                        ----------------
                                    Name: Linden Boyne
                                    Title:    CFO

Accepted and agreed as of the
date first appearing above


ARDENT PHARMACEUTICALS, INC.


By: /s/ Phillip S. Wise
    --------------------------
Name: Phillip S. Wise
Title:   CFO

By: /s/ Christopher Every
    --------------------------
    Name:  Christopher Every
    Title: President and CEO
           Enhance Biotech, Inc.



                                      -3-
<PAGE>

                                    EXHIBIT A

                                  FORM OF NOTE



                                      -4-
<PAGE>

                                    EXHIBIT B

                           FORM OF SECURITY AGREEMENT


                                      -5-